NCT05024045: Phase 1 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
The clonoSEQ® Watch Registry
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
NCT04184050: Phase 1/2: Dose Esc. & Dose Exp. of safety, Tolerability & PK of HPN217 in RRMM
NCT03761108: Phase 1/2 - REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Refractory MM
NCT03486067: Phase 1 - CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in relapsed Multiple Myeloma
NCT03430011: Phase 1/2 - Autologous BCMA-specific CAR-T cells JCARH125 in RRMM (EVOLVE)
NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
NCT03530683: Phase 1: A Trial of TTI-622 in Patients With Advanced Hem. Malignancies (TTI-622-01)
NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Myeloma